Literature DB >> 29426734

Inclusion body myositis and human immunodeficiency virus type 1: A new case report and literature review.

Priscille Couture1, Edoardo Malfatti2, Geneviève Morau3, Alexis Mathian4, Fleur Cohen-Aubart4, Hubert Nielly4, Zahir Amoura4, Patrick Cherin4.   

Abstract

Prevalence of muscle disease in human immunodeficiency virus (HIV) infection is less than 1% of patients with acquired immune deficiency syndrome. Sporadic inclusion body myositis (IBM) is observed in a few cases of patients infected by retroviruses such as HIV-1. A Caucasian man was diagnosed with HIV when he was 30 years old. The viral load was undetectable and CD4 cell count was 600/mm3 when the diagnosis of inclusion body myositis was confirmed. Histological findings were typical of IBM. The treatment consisted of immunoglobulin therapy for three years without effect. Twenty-two patients were found in the English and French literature. They are younger than those who suffer from IBM without HIV (median age = 47, range: 30 to 59), and they are mostly men with considerable serum creatine kinase (CK) elevation (median CK level = 1322 IU/L, range: 465 to 10270), most of them were treated with Zidovudine.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Human immunodeficiency virus type 1; Inclusion body myositis; Premature aging

Mesh:

Substances:

Year:  2018        PMID: 29426734     DOI: 10.1016/j.nmd.2018.01.005

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  2 in total

Review 1.  Neuromuscular Complications of SARS-CoV-2 and Other Viral Infections.

Authors:  Sarah Jacob; Ronak Kapadia; Tyler Soule; Honglin Luo; Kerri L Schellenberg; Renée N Douville; Gerald Pfeffer
Journal:  Front Neurol       Date:  2022-06-24       Impact factor: 4.086

2.  Identification of Hub Genes and Biological Pathways in Inclusion Body Myositis Using Bioinformatics Analysis.

Authors:  Yue Wu; Zijun Zhao; Jinru Zhang; Yaye Wang; Xueqin Song
Journal:  Int J Gen Med       Date:  2022-02-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.